Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Jun 9:21:105.
doi: 10.11604/pamj.2015.21.105.5469. eCollection 2015.

Resistance pattern of enterobacteriaceae isolates from urinary tract infections to selected quinolones in Yaoundé

Affiliations

Resistance pattern of enterobacteriaceae isolates from urinary tract infections to selected quinolones in Yaoundé

Emilia Enjema Lyonga et al. Pan Afr Med J. .

Abstract

Introduction: It is estimated that 150 million urinary tract infections (UTIs) occur yearly worldwide, resulting in more than 6 billion dollar in direct healthcare cost. The etiology of UTIs is predictable, with Escherichia coli, an Enterobacteriaceae being the principal pathogen. Quinolones are usually the drug of choice. In this study, we report the resistance pattern of Enterobacteriaceae isolates from UTIs to quinolones among in-patients and out-patients at the Yaoundé Reference Hospital in Cameroon.

Methods: A cross-sectional descriptive study was carried out for a ten-month period. Consecutive clean-catch mid-stream urine samples were collected from 207 in and out-patients. Identification was done using the Api 20E, and susceptibility testing using the Kirby Bauer's disc diffusion method and the MIC was done using the E-test.

Results: Out of the 207 isolates, 58(28.0%) were found to be resistant to all the quinolones used in the study. The resistances observed by species were in the order: Enterobacter 4(30.8%); Klebsiella 19(29.7%); Escherichia 25 (29.4%); Proteus 2(11.8%); Serratia 4(25.0%). Quinolone resistance for Escherichia was 42.9% for In-Patients (IP) and 16.3% for Out-Patient (OP) (P-value=0.006); Klebsiella 35.9% for IP and 20% for OP; Proteus 11.1% for IP and 12.5% for OP; Serratia 18.2% for IP and 40% for OP; Enterobacter 22.2 for IP and 50% for OP.

Conclusion: High resistance rates to quinolones were observed not only for in-patients but also for out-patients with urinary tract enterobacterial infections. These findings demonstrate the importance of antibiotics susceptibility testing in improving quinolones prescription practices in Cameroon.

Keywords: Quinolone; enterobacteriaceae; resistance; urinary tract infections.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The resistance rate of the enterobacteriaceae isolates to the selected quinolones

Similar articles

Cited by

References

    1. Stamm WE, Norrby RS. Urinary Tract infections: Disease panorama and challenges. Journal of Infectious Diseases. 2001;183(1) Suppl1:S1–4. - PubMed
    1. Oliphant Catherine M, Green Gary M. Quinolones: a Comprehensive Review. American Family Physician. 2002;65(3):445–464. - PubMed
    1. Karlowsky JA, Jones ME, Thornsberry C, Critchley I, Kelly LJ, Sahm DF. Prevalence of antimicrobial resistance among urinary tract pathogens isolated from female outpatients across the US in 1999. International Journal of Antimicrobial Agents. 2001;18(2):121–127. - PubMed
    1. Arslan Hande, Azap Ozlem Kurt, Ergönül Onder, Timurkarynak Funda. Risk factors for ciprofloxacin resistance among Escherichia coli strains isolated from urinary tract infecttions in Turkey. Journal of Antimicrobial Chemotherapy. 2005;56(5):914–918. - PubMed
    1. Andriole Vincent T. An overview of fluoroquinolones focus on moxifloxacin; Modern Medicine; 2002. June 01. Managed Healthcare Executive.

MeSH terms